DELTA-TYPE
MOLECULAR TARGETDelta-type opioid receptor (human)
DELTA-TYPE (Delta-type opioid receptor (human)) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting DELTA-TYPE
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Naloxone | 1.95 | 6 |
| 2 | Morphine | 1.79 | 5 |
| 3 | Clotrimazole | 1.10 | 2 |
| 4 | Econazole | 1.10 | 2 |
| 5 | Fentanyl | 1.10 | 2 |
| 6 | Levorphanol | 1.10 | 2 |
| 7 | Miconazole | 1.10 | 2 |
| 8 | Nalbuphine | 1.10 | 2 |
| 9 | Amoxapine | 0.69 | 1 |
| 10 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 11 | Butorphanol | 0.69 | 1 |
| 12 | candesartan cilexetil [Supplementary Concept] | 0.69 | 1 |
| 13 | Fluspirilene | 0.69 | 1 |
| 14 | Loxapine | 0.69 | 1 |
| 15 | Rifaximin | 0.69 | 1 |
About DELTA-TYPE as a Drug Target
DELTA-TYPE (Delta-type opioid receptor (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented DELTA-TYPE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
DELTA-TYPE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.